AbbVie's RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis

Mount Carmel Register

Oct 7, 2021

AbbVie's RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis |!| Mount Carmel